NIH AIDS Research & Reference Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240-686-4740
Fax: 301-515-4015
aidsreagent.org

DATA SHEET

Reagent:	HIV-1 Aspartyl Protease Substrate
Catalog Number:	1784
Lot Number:	1 #623B
Provided:	1.0 mg, lyophilized.
Sequence:	Pca-Gly-Thr-Val-Ser-Phe-Asn-Tyr-Pro-Gln-Ile-Thr-Lys-NH2.
Purity:	>95% pure by amino acid composition analysis and HPLC.
Synthesis:	Solid phase synthesis using BOC chemistry. Purified by reverse-phase chromatography in 0.1% trifluoroacetic acid and acetonitrile.
Solubility:	Soluble in water and buffer solutions.
Special Characteristics:	The cleavage products are stable, easily separated by reverse phase HPLC, and can be detected by UV absorbance at a low wavelength. The peptide can be tritiated and used in radiochemical enzyme assays. Proteolysis of HIV-1 Aspartyl Protease Substrate
Recommended Storage:	-20°C.
Contributor:	Dr. Martha Knight, Peptide Technologies.
References:	Darke PL, Nutt RF, Brady SF, Garsky VM, Ciccarone TM, Leu CT, Lumma PK, Freidinger RM, Veber DF, Sigal IS. HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins. *Biochem Biophys Res Commun* **156**:297-303, 1988. Knight M, Ito Y, Takahashi K, Chandrasekhar B, Mukherjee AB. Purification of the HIV-1 asparlyt proteinase substrate peptide. In: *Modern Countercurrent Chromatography,* Conway WD, Petroski R (Eds.), ACS Symposium Series 593, pp 111-118, Washington DC, 1995.

1995.

NOTE: Acknowledgement for publications should read: "The following reagent was obtained through the AIDS Research and Reference Reagent Program, NIAID, NIH: HIV-1 Aspartyl Protease Substrate from Peptide Technologies." Also include the reference cited above in any publications.

Limited to one mg per laboratory. Larger quantities of this peptide are available commercially from Peptide Technologies Corporation, 8401 Helgerman Court, Gaithersburg, MD 20877, TEL: 301-869-7306 or 800-966-3384; FAX: 301-869-7308.

Last Updated: July 20, 2012